Sign in or create an account to add this stock to your watchlist.
About AxoGen (NASDAQ:AXGN)
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800
Debt
Debt-to-Equity Ratio0.82
Current Ratio3.32
Quick Ratio2.81
Price-To-Earnings
Trailing P/E Ratio-139.19
Forward P/E Ratio-114.87
P/E GrowthN/A
Sales & Book Value
Annual Sales$60.43 million
Price / Sales25.06
Cash FlowN/A
Price / CashN/A
Book Value$0.63 per share
Price / Book69.29
Profitability
EPS (Most Recent Fiscal Year)($0.31)
Net Income$-10,440,000.00
Net Margins-18.83%
Return on Equity-61.66%
Return on Assets-21.29%
Miscellaneous
Employees199
Outstanding Shares34,700,000
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) announced its quarterly earnings results on Monday, April, 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.11). The medical equipment provider earned $17.30 million during the quarter, compared to the consensus estimate of $17.16 million. AxoGen had a negative net margin of 18.83% and a negative return on equity of 61.66%. The business's quarterly revenue was up 41.8% compared to the same quarter last year. View AxoGen's Earnings History.
What price target have analysts set for AXGN?
8 analysts have issued 1 year target prices for AxoGen's shares. Their forecasts range from $21.00 to $45.00. On average, they anticipate AxoGen's share price to reach $35.5714 in the next year. View Analyst Ratings for AxoGen.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include Masimo (MASI), LivaNova (LIVN), Getinge Group (GNGBY), CONMED (CNMD), NxStage (NXTM), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Biolife Solutions (BLFS) and Zynex (ZYXI).
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Pres, CEO & Director (Age 56)
- Mr. Peter J. Mariani, CFO & Principal Accounting Officer (Age 54)
- Mr. Gregory G. Freitag, Gen. Counsel, Sr. VP of Bus. Devel. & Director (Age 56)
- Mr. Shawn F. McCarrey, Sr. VP of Sales (Age 60)
- Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)
Has AxoGen been receiving favorable news coverage?
Press coverage about AXGN stock has trended somewhat negative recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AxoGen earned a media sentiment score of -0.19 on Accern's scale. They also gave news articles about the medical equipment provider an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are AxoGen's major shareholders?
AxoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.94%), Opaleye Management Inc. (4.94%), Wells Fargo & Company MN (2.06%), Rock Springs Capital Management LP (1.46%), Lord Abbett & CO. LLC (1.04%) and Next Century Growth Investors LLC (1.02%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Guido J Neels, James E Flynn, Jamie Mark Grooms, John P Engels, Joseph M Mandato, Karen L Zaderej, Peter J Mariani, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.
Which institutional investors are selling AxoGen stock?
AXGN stock was sold by a variety of institutional investors in the last quarter, including Next Century Growth Investors LLC, Opaleye Management Inc., Russell Investments Group Ltd., Cortina Asset Management LLC, Bamco Inc. NY, Eversept Partners LLC, Timpani Capital Management LLC and Millrace Asset Group Inc.. Company insiders that have sold AxoGen company stock in the last year include Guido J Neels, Jamie Mark Grooms, Robert James Rudelius and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen.
Which institutional investors are buying AxoGen stock?
AXGN stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Eagle Asset Management Inc., Atlantic Trust Group LLC, Lord Abbett & CO. LLC, Lisanti Capital Growth LLC, Citadel Advisors LLC and Rock Springs Capital Management LP. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, John P Engels, Karen L Zaderej and Peter J Mariani. View Insider Buying and Selling for AxoGen.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $43.65.
How big of a company is AxoGen?
AxoGen has a market capitalization of $1.52 billion and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen employs 199 workers across the globe.
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
AxoGen (NASDAQ:AXGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for AxoGen in the last 12 months. Their average twelve-month price target is $35.5714, suggesting that the stock has a possible downside of 18.51%. The high price target for AXGN is $45.00 and the low price target for AXGN is $21.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $35.5714 | $33.1429 | $29.3333 | $24.40 |
| Price Target Upside: | 18.51% downside | 11.97% downside | 10.07% upside | 0.41% upside |
AxoGen (NASDAQ:AXGN) Consensus Price Target History
AxoGen (NASDAQ:AXGN) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
AxoGen (NASDAQ:AXGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AxoGen (NASDAQ AXGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.86%
Institutional Ownership Percentage: 71.02%
AxoGen (NASDAQ AXGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Shawn F Mccarrey | SVP | Sell | 10,000 | $43.47 | $434,700.00 | 33,057 |  |
| 2/20/2018 | Jamie Mark Grooms | Director | Sell | 63,395 | $27.67 | $1,754,139.65 | 5,827 | |
| 2/15/2018 | Jamie Mark Grooms | CFO | Sell | 95,712 | $26.84 | $2,568,910.08 | | |
| 2/13/2018 | Jamie Mark Grooms | CFO | Sell | 10,300 | $26.21 | $269,963.00 | | |
| 12/12/2017 | Jamie Mark Grooms | Director | Sell | 38,405 | $26.35 | $1,011,971.75 | | |
| 12/8/2017 | Jamie Mark Grooms | Director | Sell | 84,295 | $26.38 | $2,223,702.10 | | |
| 12/6/2017 | Jamie Mark Grooms | Director | Sell | 21,290 | $26.22 | $558,223.80 | | |
| 11/20/2017 | Guido J Neels | Director | Sell | 1,150,000 | $19.74 | $22,701,000.00 | | |
| 9/11/2017 | Robert James Rudelius | Director | Sell | 16,143 | $18.00 | $290,574.00 | 43,273 | |
| 10/7/2016 | Amy Mcbride Wendell | Director | Buy | 13,333 | $7.50 | $99,997.50 | 13,333 | |
| 10/7/2016 | John P Engels | VP | Buy | 4,000 | $7.50 | $30,000.00 | 98,425 | |
| 10/7/2016 | Karen L Zaderej | CEO | Buy | 10,000 | $7.50 | $75,000.00 | 242,147 | |
| 10/7/2016 | Peter J Mariani | CFO | Buy | 3,333 | $7.50 | $24,997.50 | 3,333 | |
| 8/9/2016 | Joseph M Mandato | Director | Sell | 149,618 | $8.54 | $1,277,737.72 | | |
| 8/8/2016 | Joseph M Mandato | Director | Sell | 107,450 | $8.63 | $927,293.50 | | |
| 7/21/2016 | James E Flynn | Insider | Sell | 102,136 | $6.70 | $684,311.20 | | |
| 7/18/2016 | James E Flynn | Insider | Sell | 279,303 | $7.53 | $2,103,151.59 | | |
| 9/18/2015 | James E Flynn | Insider | Sell | 345,000 | $5.50 | $1,897,500.00 | | |
| 6/3/2015 | Joseph M Mandato | Director | Buy | 6,500 | $3.10 | $20,150.00 | | |
| 6/2/2015 | Lee Robert Johnston Jr | Insider | Buy | 5,000 | $3.06 | $15,300.00 | | |
| 4/8/2015 | James E Flynn | Insider | Sell | 144,385 | $3.25 | $469,251.25 | | |
| 12/10/2014 | Lee Robert Johnston Jr | CFO | Buy | 10,000 | $3.06 | $30,600.00 | | |
| 8/12/2014 | Mark Stephen Gold | Director | Buy | 20,000 | $2.29 | $45,800.00 | | |
| 8/8/2014 | Mark Stephen Gold | Director | Buy | 11,000 | $2.31 | $25,410.00 | | |
| 6/6/2014 | Lee Robert Johnston Jr | CFO | Buy | 10,000 | $2.58 | $25,800.00 | | |
| 6/3/2014 | Gregory Gene Freitag | CFO | Buy | 5,200 | $2.45 | $12,740.00 | | |
| 6/3/2014 | Karen L Zaderej | CEO | Buy | 5,000 | $2.43 | $12,150.00 | | |
| 5/20/2014 | Jill F Schiaparelli | SVP | Buy | 2,000 | $2.63 | $5,260.00 | | |
| 5/12/2014 | Karen L Zaderej | CEO | Buy | 5,000 | $2.70 | $13,500.00 | | |
| 5/7/2014 | Mark Stephen Gold | Director | Buy | 1,977 | $2.60 | $5,140.20 | | |
| 3/13/2014 | Karen L Zaderej | CEO | Buy | 1,500 | $3.49 | $5,235.00 | | |
| 8/29/2013 | Shawn F Mccarrey | SVP | Buy | 25,000 | $3.21 | $80,250.00 | | |
| 8/24/2013 | Shawn F Mccarrey | SVP | Buy | 5,000 | $3.00 | $15,000.00 | | |
| 8/14/2013 | Jill F Schiaparelli | SVP | Buy | 5,000 | $3.00 | $15,000.00 | | |
| 8/14/2013 | John Frederick Harper | Director | Buy | 66,666 | $3.00 | $199,998.00 | | |
| 8/14/2013 | Karen L Zaderej | CEO | Buy | 8,334 | $3.00 | $25,002.00 | | |
| 12/4/2012 | Jill F Schiaparelli | SVP | Buy | 2,000 | $2.55 | $5,100.00 | | |
| 11/29/2012 | Jill F Schiaparelli | SVP | Buy | 1,000 | $2.70 | $2,700.00 | | |
| 11/15/2012 | Jill F Schiaparelli | SVP | Buy | 2,750 | $2.56 | $7,040.00 | | |
| 10/1/2012 | John Frederick Harper | Director | Buy | 86,557 | $3.61 | $312,470.77 | | |
(Data available from 1/1/2013 forward)
AxoGen (NASDAQ AXGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Reviewing AxoGen (AXGN) and Biolife Solutions (BLFS)
www.americanbankingnews.com - May 22 at 1:25 PM |
| Brokerages Expect AxoGen, Inc (AXGN) Will Announce Quarterly Sales of $21.07 Million
www.americanbankingnews.com - May 22 at 2:14 AM |
 | BRIEF-Axogen, Inc. Announces Appointment Of Karen Zaderej As Chairman Of The Board
www.reuters.com - May 21 at 9:16 AM |
 | AxoGen, Inc. Announces Appointment of Karen Zaderej as Chairman of the Board
finance.yahoo.com - May 21 at 9:16 AM |
| AxoGen, Inc (AXGN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 21 at 8:50 AM |
| Analysts Anticipate AxoGen, Inc (AXGN) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - May 20 at 9:28 PM |
| BRIEF-Axogen Inc Says On May 15, Board Elected CEO Zaderej To Succeed Grooms As Chairman
www.reuters.com - May 19 at 9:23 AM |
| AxoGen, Inc (AXGN) SVP Shawn F. Mccarrey Sells 10,000 Shares
www.americanbankingnews.com - May 18 at 7:55 PM |
| Head to Head Contrast: AxoGen (AXGN) vs. Viveve Medical (VIVE)
www.americanbankingnews.com - May 17 at 1:31 PM |
| William Blair Equities Analysts Raise Earnings Estimates for AxoGen, Inc (AXGN)
www.americanbankingnews.com - May 16 at 7:26 AM |
| BRIEF-Axogen Inc Announces Closing Of Public Offering Of Common Stock
www.reuters.com - May 15 at 4:48 PM |
| AxoGen, Inc. Announces Closing of Public Offering of Common Stock
finance.yahoo.com - May 14 at 10:18 AM |
 | AxoGen (AXGN) Prices Upsized 3M Share Offering at $41
www.streetinsider.com - May 11 at 10:23 AM |
| Analyzing CHF Solutions (CHFS) and AxoGen (AXGN)
www.americanbankingnews.com - May 10 at 11:50 AM |
| BRIEF-AxoGen Upsizes Public Offering To 3 Mln Shares At $41 Per Share
www.reuters.com - May 9 at 4:31 PM |
| AxoGen, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock
finance.yahoo.com - May 9 at 9:30 AM |
| BRIEF-AxoGen Announces Proposed Public Offering Of Common Stock
www.reuters.com - May 8 at 9:23 AM |
| AxoGen (AXGN) to Offer 2M Shares
www.streetinsider.com - May 8 at 9:23 AM |
| AxoGen Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 7 at 4:37 PM |
| AxoGen, Inc (AXGN) Expected to Announce Quarterly Sales of $21.07 Million
www.americanbankingnews.com - May 5 at 3:52 AM |
| AxoGen (AXGN) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - May 4 at 12:21 AM |
| -$0.09 Earnings Per Share Expected for AxoGen, Inc (AXGN) This Quarter
www.americanbankingnews.com - May 3 at 5:56 PM |
| FY2018 EPS Estimates for AxoGen, Inc Lowered by Analyst (AXGN)
www.americanbankingnews.com - May 3 at 9:52 AM |
| Jefferies Group Weighs in on AxoGen, Inc's Q2 2018 Earnings (AXGN)
www.americanbankingnews.com - May 3 at 9:01 AM |
| Q2 2018 EPS Estimates for AxoGen, Inc Decreased by Leerink Swann (AXGN)
www.americanbankingnews.com - May 3 at 9:01 AM |
| AxoGen, Inc (AXGN) Forecasted to Post Q2 2018 Earnings of ($0.05) Per Share
www.americanbankingnews.com - May 3 at 9:01 AM |
| Leerink Swann Analysts Reduce Earnings Estimates for AxoGen, Inc (AXGN)
www.americanbankingnews.com - May 2 at 10:21 AM |
| Analysts Offer Predictions for AxoGen, Inc's FY2019 Earnings (AXGN)
www.americanbankingnews.com - May 2 at 10:02 AM |
 | AxoGen, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 1 at 4:24 PM |
| AxoGen (AXGN) Price Target Increased to $43.00 by Analysts at JMP Securities
www.americanbankingnews.com - May 1 at 10:42 AM |
| AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 1 at 9:28 AM |
| Edited Transcript of AXGN earnings conference call or presentation 30-Apr-18 8:30pm GMT
finance.yahoo.com - May 1 at 9:28 AM |
| AxoGen: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 9:28 AM |
| Cantor Fitzgerald Reaffirms "Overweight" Rating for AxoGen (AXGN)
www.americanbankingnews.com - May 1 at 9:08 AM |
| AxoGen (AXGN) Announces Quarterly Earnings Results
www.americanbankingnews.com - April 30 at 9:14 PM |
| AxoGen (AXGN) Misses Q1 EPS by 5c
www.streetinsider.com - April 30 at 4:26 PM |
| BRIEF-AxoGen Reports Q1 Loss Per Share Of $0.16
www.reuters.com - April 30 at 4:26 PM |
| AxoGen, Inc. Reports 2018 First Quarter Financial Results
finance.yahoo.com - April 30 at 4:26 PM |
| Reviewing AxoGen (AXGN) and The Competition
www.americanbankingnews.com - April 29 at 7:55 AM |
| Head to Head Analysis: AxoGen (AXGN) & Its Peers
www.americanbankingnews.com - April 28 at 3:06 AM |
| AxoGen (AXGN) & Its Peers Head-To-Head Comparison
www.americanbankingnews.com - April 28 at 1:20 AM |
| AxoGen (AXGN) vs. Its Peers Financial Analysis
www.americanbankingnews.com - April 26 at 1:27 PM |
| AxoGen, Inc (AXGN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 26 at 9:53 AM |
| AxoGen (AXGN) & Its Peers Critical Analysis
www.americanbankingnews.com - April 25 at 5:20 AM |
| AxoGen (AXGN) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 23 at 9:20 AM |
| AxoGen (AXGN) & Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - April 22 at 7:06 PM |
| AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
finance.yahoo.com - April 18 at 9:29 AM |
 | AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
feeds.benzinga.com - April 18 at 7:52 AM |
| Zacks: Brokerages Expect AxoGen, Inc (AXGN) Will Post Quarterly Sales of $17.21 Million
www.americanbankingnews.com - April 18 at 3:58 AM |
| AxoGen, Inc (AXGN) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM |
AxoGen (NASDAQ:AXGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AxoGen (NASDAQ:AXGN) Income Statement, Balance Sheet and Cash Flow Statement
AxoGen (NASDAQ AXGN) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
